Article
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2024
Nassar Amin H, Kim So Yeon, Aredo Jacqueline V, Feng Jamie, Shepherd Frances, Xu Chao, Kaldas David, Gray Jhanelle E, Dilling Thomas J, Neal Joel W, Wakelee Heather A, Liu Yufei, Lin Steven H, Abuali Tariq, Amini Arya, Nie Yunan, Patil Tejas, Lobachov Anastasiya, Bar Jair, Fitzgerald Bailey, Fujiwara Yu, Marron Thomas U, Thummalapalli Rohit, Yu Helena, Owen Dwight H, Sharp John, Farid Saira, Rocha Pedro, Arriola Edurne, D'Aiello Angelica, Cheng Haiying, Whitaker Ryan, Parikh Kaushal, Ashara Yash, Chen Luxi, Sankar Kamya, Harris Jeremy P, Nagasaka Misako, Ayanambakkam Adanma, Velazquez Ana I, Ragavan Meera, Lin Jessica J, Piotrowska Zofia, Wilgucki Molly, Reuss Joshua, Luders Heike, Grohe Christian, Baena Espinar Javier, Feiner Ella, Punekar Salman R, Gupta Shruti, Leal Ticiana, Kwiatkowski David J, Mak Raymond H, Adib Elio, Naqash Abdul Rafeh, Goldberg Sarah B
Abstract excerpt
INTRODUCTION: Durvalumab improves survival when used as consolidation therapy after chemoradiation (CRT) in patients with stage III NSCLC. The optimal consolidation therapy for patients with EGFR-mutant (EGFRmut) stage III NSCLC remains unknown. METHODS: In this multi-institutional, international retrospective analysis across 24 institutions, we evaluated outcomes in patients with stage III EGFRmut NSCLC treated...
Read the complete abstract on PubMed